Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
The Globe and Mail15d
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
The stock is up 8.6% since reporting and currently trades at $510.02. Is now the time to buy Vertex Pharmaceuticals? Access ...
Benzinga.com20d
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...
The Motley Fool22d
Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever
Generative AI should continue to provide a huge tailwind for Amazon's cloud unit. Vertex Pharmaceuticals gives investors a way to zig when the market is zagging. When you're on an airplane ...
The Motley Fool23d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
City News28d
510 streetcar to return on March 30, 509 to be fully suspended
After pushing back the return of the 510 Spadina streetcar by about three months, the TTC says it will be back on track on March 30. The route was suspended and replaced by buses in June of 2024 for ...
BioPharma Dive28d
Vertex’s new pain drug gets first coverage nod from major insurer
Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...